PT  - JOURNAL ARTICLE
AU  - Sibyle Etievant
AU  - Antonin Bal
AU  - Vanessa Escuret
AU  - Karen Brengel–Pesce
AU  - Maude Bouscambert
AU  - Valérie Cheynet
AU  - Laurence Generenaz
AU  - Guy Oriol
AU  - Gregory Destras
AU  - Geneviève Billaud
AU  - Laurence Josset
AU  - Emilie Frobert
AU  - Florence Morfin
AU  - Alexandre Gaymard
TI  - Sensitivity assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories
AID  - 10.1101/2020.05.03.20072207
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.03.20072207
4099  - http://medrxiv.org/content/early/2020/05/04/2020.05.03.20072207.short
4100  - http://medrxiv.org/content/early/2020/05/04/2020.05.03.20072207.full
AB  - The sensitivity of SARS-CoV-2 RT-PCR tests developed by Charité (Germany), HKU (Hong-Kong), China CDC (China), US CDC (United-States), and Institut Pasteur, Paris (France) was assessed on SARS-CoV-2 cell culture supernatants and clinical samples. Although all RT-PCR assays performed well for SARS-CoV-2 detection, RdRp Institut Pasteur (IP2, IP4), N China CDC, and N1 US CDC were found to be the most sensitive.Competing Interest StatementSE, VE, MB, GD, GB, LJ, EF, FM, AG have no conflicts of interest. AB has received a research grant from bioMérieux. KBP, VC, LG and GO are employees at bioMérieux.Funding StatementNo specific funding. Reagents were provided by Laboratoire Commun de Recherche Hospices Civils de Lyon – bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request